Litigation Details for Orexo AB v. Actavis Elizabeth LLC (D. Del. 2016)

Orexo AB v. Actavis Elizabeth LLC (D. Del. 2016)

Docket	1:16-cv-00062	Date Filed	2016-02-02
Court	District Court, D. Delaware	Date Terminated	2019-01-10
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To	Sherry R. Fallon
Patents	8,454,996; 8,470,361; 8,658,198; 8,940,330
Link to Docket	External link to docket

Details for Orexo AB v. Actavis Elizabeth LLC (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-02-02				External link to document
2016-02-01	1		27. United States Patent No. 8,454,996 (“the ’996 patent,” copy attached as Exhibit A) … I Infringement of U.S. Patent No. 8,454,996 Under 35 U.S.C. § 271 …respect to the ’996 patent, the ’330 patent, the ’361 patent, and the ’198 patent. …before the expiration of the ’996 patent, the ’330 patent, and U.S. Patent Nos. 8,470,361 and 8,658,198 (… This is an action for patent infringement arising under the Patent Laws of the United States and	External link to document
2016-02-01	10		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,454,996 B2; 8,940,330 B2; 8,658,198…2016 10 January 2019 1:16-cv-00062 830 Patent None District Court, D. Delaware	External link to document
2016-02-01	28		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,454,996 B2 ;8,940,330 B2. (…2016 10 January 2019 1:16-cv-00062 830 Patent None District Court, D. Delaware	External link to document

Orexo AB v. Actavis Elizabeth LLC, 1:16-cv-00062: Litigation Summary and Patent Analysis

Last updated: August 8, 2026

Orexo AB defeated Actavis Elizabeth LLC’s Hatch-Waxman challenge to the patent covering Zubsolv, Orexo’s buprenorphine/naloxone sublingual tablet for opioid dependence. The litigation centered on U.S. Patent No. 8,940,330, which protects a rapidly dissolving formulation incorporating buprenorphine, naloxone, citric acid and mannitol. The Federal Circuit affirmed the district court’s judgment that the asserted claims were not invalid for obviousness, leaving Actavis unable to launch its proposed generic before the patent’s expiration based on the record in this case. [1]

What drug and patent were at issue in Orexo v. Actavis?

The case involved Zubsolv, a sublingual tablet containing buprenorphine hydrochloride and naloxone hydrochloride. Orexo developed Zubsolv as an alternative to Suboxone sublingual products, with differences in tablet composition, dissolution characteristics, taste and dosing profile.

The principal patent was:

Patent	Subject matter	Patent holder	Litigation significance
U.S. Patent No. 8,940,330	Buprenorphine/naloxone sublingual pharmaceutical composition	Orexo AB	Primary patent upheld against Actavis’s validity challenge

The asserted patent claimed a pharmaceutical composition designed to dissolve in the mouth and deliver buprenorphine and naloxone. The formulation used an effervescent or acid-based approach intended to improve dissolution and product performance compared with earlier buprenorphine/naloxone products. [1]

Orexo sued after Actavis filed an abbreviated new drug application seeking approval for a generic version of Zubsolv. Actavis’s filing included Paragraph IV certifications asserting that the relevant patent was invalid, unenforceable or would not be infringed.

What was the procedural history of the case?

The principal procedural milestones were:

Date	Event
January 29, 2016	Orexo filed the patent infringement action in the District of Delaware
2016-2017	The parties litigated infringement and validity issues arising from Actavis’s ANDA
2017	The District of Delaware ruled in Orexo’s favor on the asserted patent
August 22, 2018	The Federal Circuit affirmed the district court’s judgment in Orexo’s favor
Post-appeal	Actavis did not obtain a judicial pathway to launch the challenged generic before the patent’s expiration

The Federal Circuit decision is reported at 903 F.3d 1265. The appeal focused on whether the claimed Zubsolv formulation would have been obvious in view of the prior art, including Suboxone-related products and formulation references. [1]

What did the Federal Circuit decide?

The Federal Circuit affirmed the district court’s determination that the asserted claims of the ’330 patent were not obvious.

The court’s analysis turned on the interaction of several formulation variables:

• The relative amounts of buprenorphine and naloxone.
• The use of citric acid.
• The use of mannitol.
• Tablet dissolution behavior.
• Taste and patient acceptability.
• The practical difficulty of reproducing the claimed formulation from the prior art.

Actavis argued that a skilled formulator would have been motivated to modify the known Suboxone formulation and would have had a reasonable expectation of success. The Federal Circuit rejected that position after reviewing the district court’s factual findings.

The court gave weight to evidence that the claimed formulation produced unexpected results. The formulation had a faster dissolution profile and improved taste characteristics relative to the prior product. Those results supported nonobviousness because the prior art did not establish that the claimed combination of ingredients would predictably produce the observed performance.

The Federal Circuit also rejected the argument that the claimed formulation was simply a predictable optimization of known ingredients. The relevant inquiry was not whether each ingredient was individually known. It was whether the prior art would have directed a skilled artisan to the claimed combination with a reasonable expectation of success. [1]

How strong was Orexo’s patent position?

Orexo’s position was strong after the Federal Circuit ruling because the key validity challenge failed at both the district court and appellate levels.

Strengths of the ’330 patent

The patent benefited from four litigation strengths:

1. The claims were tied to a specific pharmaceutical composition rather than only a broad therapeutic use.
2. The formulation produced commercially relevant performance differences, including dissolution and taste.
3. Orexo presented evidence of unexpected results.
4. The Federal Circuit affirmed the lower court’s fact-intensive obviousness findings.

The case illustrates the value of formulation patents in pharmaceutical litigation. A generic applicant may be able to reproduce the active ingredients and dosage form while still facing infringement risk from excipient selection, ingredient ratios, dissolution behavior or manufacturing parameters.

Limitations of the result

The decision did not establish that every patent covering Zubsolv was valid or infringed. It resolved the issues presented in the Actavis litigation, particularly the validity challenge to the asserted claims of the ’330 patent. It also did not create a general rule that every improved formulation is patentable.

The decision’s commercial effect depended on the scope of the asserted claims and the design of Actavis’s proposed ANDA product. A later generic applicant could attempt to design around the patent, challenge other Orange Book-listed patents or pursue a different litigation strategy.

When does the Zubsolv patent lose exclusivity?

The ’330 patent had a listed term extending into 2029. Patent-term calculations can be affected by patent-term adjustment, terminal disclaimers and pediatric exclusivity. The litigation record and Federal Circuit decision did not create a new expiration date.

The practical exclusivity timeline was:

Exclusivity mechanism	Relevance to Zubsolv
FDA approval	Zubsolv received FDA approval in 2013
Regulatory exclusivity	The product was a new formulation of previously known active ingredients, rather than a conventional new chemical entity
Patent protection	The ’330 patent provided the principal barrier litigated against Actavis
Generic approval restriction	The ANDA dispute triggered the Hatch-Waxman stay and patent litigation
Post-judgment position	Actavis remained blocked by the upheld patent claims unless it prevailed through another legal or regulatory route

Zubsolv did not receive biologic exclusivity because it is a small-molecule drug. Biosimilar provisions under the Public Health Service Act do not apply. Any follow-on product would proceed through the ANDA pathway, subject to patent certifications and applicable exclusivity rules.

What was the Paragraph IV challenge?

Actavis filed an ANDA for a generic version of Zubsolv and submitted Paragraph IV certifications against Orexo’s patent rights. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or not infringed.

Orexo’s lawsuit was therefore a standard Hatch-Waxman patent action. The filing of the complaint imposed the statutory 30-month stay on FDA approval of the ANDA, subject to statutory exceptions and court orders.

The commercial purpose of the challenge was to obtain approval before the patent’s expiration. Actavis had to prove either that:

• Its generic did not infringe the asserted claims;
• The claims were invalid;
• The patent was unenforceable; or
• The patent did not lawfully block approval.

The reported appellate decision primarily addressed obviousness. The Federal Circuit’s affirmance removed the central validity basis for an early generic launch.

What formulations were protected by the Orexo patent?

The ’330 patent protected a sublingual formulation containing buprenorphine and naloxone in a tablet designed for oral dissolution. The formulation included excipients that influenced dissolution, taste and dosage delivery.

Formulation elements relevant to the litigation

The litigation focused on:

• Buprenorphine as the opioid partial agonist.
• Naloxone as an abuse-deterrent component.
• Citric acid as a formulation component affecting the tablet environment and dissolution.
• Mannitol as a diluent or excipient.
• The tablet’s rapid dissolution characteristics.
• The relationship between the formulation and patient taste perception.

The case is relevant to pharmaceutical companies because it demonstrates how a formulation patent can protect a product after the active ingredients are already known. The commercial product may remain exposed to generic competition, but a technically narrow formulation patent can delay entry if the generic product falls within the claims.

What was the relationship to Suboxone?

Suboxone was the principal commercial and technical comparator. Suboxone also contained buprenorphine and naloxone and was marketed for opioid dependence treatment.

Actavis argued that the prior art, including Suboxone-related knowledge, supplied the motivation to develop the claimed Zubsolv formulation. Orexo countered that the prior art did not make the claimed combination predictable and that Zubsolv’s performance results were unexpected.

The comparison can be summarized as follows:

Issue	Suboxone-related prior art	Zubsolv formulation
Active ingredients	Buprenorphine and naloxone	Buprenorphine and naloxone
Dosage form	Sublingual product	Sublingual tablet
Formulation objective	Deliver both active ingredients	Improve dissolution, taste and administration characteristics
Litigation role	Prior-art basis for obviousness challenge	Claimed invention
Outcome	Did not invalidate the ’330 patent	Patent claims upheld

The case did not grant Orexo a monopoly over buprenorphine/naloxone therapy. The protection was tied to the claimed formulation and its technical limitations.

What was the FDA and Orange Book status?

Zubsolv is an FDA-approved buprenorphine/naloxone product. Orexo’s patent rights were relevant to the Orange Book because the product was approved under the NDA framework and the patent was listed against the product.

The Orange Book functioned as the regulatory trigger for Actavis’s Paragraph IV certification. Once Actavis challenged the listed patent, Orexo could file suit and obtain the statutory approval stay.

The key FDA and patent-law distinction is:

• FDA approval established the product’s approved indication and labeling.
• Orange Book listing identified patent rights associated with the approved product.
• The ANDA permitted Actavis to rely on the reference product’s safety and efficacy data.
• Paragraph IV litigation determined whether the listed patent blocked approval or launch.

FDA approval of a generic would not itself resolve patent infringement. A generic applicant can obtain regulatory approval while remaining subject to a patent injunction or launch risk.

Did Actavis and Orexo settle the litigation?

The reported Federal Circuit decision reflects an appellate judgment in Orexo’s favor. No settlement agreement is identified in the principal appellate opinion as the basis for resolution.

The outcome should therefore be treated as a litigated validity victory rather than a settlement-based entry arrangement. The public appellate record does not establish an agreed generic launch date, authorized-generic arrangement or license under which Actavis could enter before patent expiration. [1]

Which companies challenged Zubsolv patents?

Actavis Elizabeth LLC was the defendant in this case. Actavis was part of the broader Actavis pharmaceutical business, which later became associated with Allergan and, in portions of its generic operations, Teva following corporate transactions.

The case should not be treated as a complete map of all Zubsolv patent challenges. Other generic applicants could file separate ANDAs, challenge later-issued patents or pursue noninfringing formulations. The judgment directly resolved the Actavis dispute.

What generic entry risks remained after the decision?

The decision reduced immediate early-entry risk but did not eliminate all future competition risk.

Early generic launch

Actavis’s principal early-launch route was weakened because the Federal Circuit upheld the patent against the obviousness challenge. An at-risk launch could have exposed Actavis to damages and injunctive relief.

Design-around products

A generic applicant might attempt to avoid the asserted claims by changing:

• Excipient composition.
• Acid or buffering system.
• Ingredient ratios.
• Tablet structure.
• Dissolution profile.
• Manufacturing process.

A design-around would still require FDA approval and could generate a new infringement dispute.

Later patent challenges

Orexo’s broader Zubsolv patent estate could include continuation patents, formulation claims, method-of-use claims and manufacturing claims. The affirmance of the ’330 patent did not automatically determine the validity of those separate rights.

Market substitution

Even if a generic buprenorphine/naloxone product entered the market, substitution would depend on dosage strengths, formulary placement, state substitution rules, physician adoption and patient tolerance. Zubsolv’s commercial position was tied to product-specific formulation and dosing attributes, not only to the active ingredients.

What was the revenue exposure for Orexo?

Zubsolv was a core Orexo commercial product in the United States. The litigation therefore protected a material revenue stream rather than a development-stage asset.

The judgment had three commercial effects:

1. It preserved Orexo’s ability to sell Zubsolv without immediate direct generic substitution from Actavis.
2. It protected pricing and market share during the remaining patent term.
3. It increased the value of Orexo’s formulation and regulatory-development investment.

The exact revenue impact depends on Zubsolv sales, net pricing, payer mix and the timing of competing launches. The case record does not provide a reliable standalone valuation of the protected revenue stream.

Key Takeaways

• Orexo sued Actavis Elizabeth in the District of Delaware after Actavis filed a Paragraph IV ANDA challenge involving generic Zubsolv.
• The principal patent was U.S. Patent No. 8,940,330.
• The patent covered a buprenorphine/naloxone sublingual formulation with specific excipient and dissolution characteristics.
• The district court upheld the asserted claims.
• The Federal Circuit affirmed in 903 F.3d 1265.
• Unexpected formulation results supported the nonobviousness finding.
• The decision materially reduced Actavis’s ability to launch before patent expiration.
• The case involved a small-molecule generic challenge, not a biosimilar dispute.
• The ruling did not validate every Zubsolv-related patent or eliminate all future design-around risk.
• No public settlement-based entry date is established by the principal appellate record.

FAQs

Could Actavis launch a generic Zubsolv after the Federal Circuit decision?

Not on the basis of the failed validity challenge alone. A launch would have required a noninfringement position, a successful challenge to another patent, an authorized license or another legally available pathway.

Why was the Zubsolv formulation patent important if Suboxone used the same active ingredients?

The patent protected the claimed combination of ingredients and formulation characteristics, not merely buprenorphine and naloxone as active ingredients. The court found that the claimed combination was not an obvious modification of the prior art.

Does the Orexo decision apply to all buprenorphine/naloxone generics?

No. The decision applies to the patent claims and facts litigated against Actavis. Other generic products may raise different infringement and validity issues.

Was Zubsolv protected by new chemical entity exclusivity?

No. Buprenorphine and naloxone were previously known active ingredients. Zubsolv’s principal protection came from its formulation patents and applicable regulatory exclusivity for the approved product.

Is Orexo v. Actavis a biosimilar litigation precedent?

No. It is a small-molecule Hatch-Waxman case involving an ANDA and Paragraph IV patent certifications. Biosimilar litigation proceeds under a separate statutory framework.

References

1. United States Court of Appeals for the Federal Circuit. (2018). Orexo AB v. Actavis Elizabeth LLC, 903 F.3d 1265.
2. United States District Court for the District of Delaware. (2016-2018). Orexo AB v. Actavis Elizabeth LLC, No. 1:16-cv-00062.
3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
4. U.S. Patent and Trademark Office. (2015). U.S. Patent No. 8,940,330, Pharmaceutical composition.